LRRK2 and neoplasm: Furthermore, given the different off-targets of XMD8-92 (BRD4 and LRRK2) (Miller et al, 2023) and Seliciclib (CDKs), one limitation of our study is the lack of an in vivo system to demonstrate that genetic suppression of ERK5 and/or CDK5 recapitulates the anti-tumor effects observed with the inhibitors and shRNAs in vitro.